SILVER SPRING
Zimrixby biosimilar cleared for Rituxan indications
- Sponsor
- Fresenius Kabi
- Drug
- Zimrixby · rituximab-cdxx
- Indication
- oncology and autoimmune disease
FDA approves Zimrixby (rituximab-cdxx), a biosimilar referencing Rituxan, for its oncology and autoimmune disease indications.
What this means
Zimrixby is a biosimilar copy of the established drug Rituxan, a monoclonal antibody used to treat certain cancers and autoimmune diseases by targeting a specific protein on immune cells. Today FDA cleared this biosimilar for all the same uses as its reference product. This approval provides patients and healthcare systems with an additional, potentially lower-cost version of this widely used medication.